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Cancer-related anaemia is associated with a wide spectrum of symptoms that can negatively affect quality of life. Because
epoetin alfa has demonstrated efﬁcacy in correcting cancer-related anaemia, the impact of this treatment on quality of life was
evaluated in a multinational, randomised, double-blind, placebo-controlled trial in 375 anaemic cancer patients receiving non-
platinum-based chemotherapy. The cancer-speciﬁc measures of quality of life included the general scale (FACT-G Total) and
fatigue subscale (FACT-An Fatigue subscale) of the Functional Assessment of Cancer Therapy-Anaemia and the Cancer Linear
Analogue Scales measuring energy, ability to do daily activities, and overall quality of life. These measures were also used to
examine the relationship between haemoglobin levels and quality of life. Both univariate and multiple linear regression analyses
of quality of life data were performed. Results of the univariate analysis have been reported previously. The a priori-planned
multiple linear regression analysis, which accounted for the effects of disease progression and several other possibly
confounding variables on quality of life, showed a signiﬁcant advantage for epoetin alfa over placebo for the ﬁve scales (all,
P50.05), and conﬁrmed the results of the univariate analysis. For cancer-speciﬁc measures, signiﬁcant correlations were
demonstrated between baseline haemoglobin and quality of life (r, range: 0.14–0.26, all P50.05) and between change in
haemoglobin and change in quality of life (r, range: 0.26–0.34, all P50.01). These ﬁndings provide evidence that increasing
haemoglobin levels by epoetin alfa administration can signiﬁcantly improve cancer patients’ quality of life.
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Fatigue has replaced pain, nausea, and vomiting as the most
common and often the most troubling side effect of concern to
cancer patients receiving chemotherapy, with cancer patient surveys
in both Europe and the USA reporting prevalence rates between
58% and 90% (Vogelzang et al, 1997; Stone et al, 1998, 2000;
Simon and Zittoun, 1999; Curt et al, 2000). In addition, in a recent
survey of 379 individuals who had completed chemotherapy, 37%
reported at least 2 weeks of fatigue in the previous month. Of
respondents who had completed treatment over 5 years ago, 33%
still reported at least 2 weeks of fatigue in the month before the
interview (Cella et al, 2001). The aetiology of fatigue in cancer
patients is multifactorial and may include adverse effects of treat-
ment, underlying disease, metabolic and physiological
abnormalities, and other variables (Groopman, 1998). Although
fatigue can have a deleterious effect on the quality of cancer
patients’ lives, it remains poorly understood, under-investigated,
and often under-treated (Stone et al, 2000). Anaemia occurs
frequently in cancer patients (Barrett-Lee et al, 2000; Coifﬁer et
al, 2001) and is highly associated with fatigue and diminished qual-
ity of life (QoL) (Cella, 1998).
Cancer-related anaemia may be a consequence of the neoplastic
process itself; cytotoxic therapy; marrow inﬁltration by malignant
cells; renal impairment; iron, folate, or vitamin B12 deﬁciency;
infectious processes; or blood loss (Ludwig and Fritz, 1998). Anae-
mia can give rise to exhaustion, fatigue, dizziness, headache,
dyspnoea, chest pain, and impaired cognitive function, all of which
can diminish patients’ QoL (Winningham et al, 1994; Cella, 1998;
Ludwig and Fritz, 1998; Schwartz, 1998). Many cancer patients
require therapeutic intervention to correct the underlying anaemia.
In several studies reported between 1990 and 2001, recombinant
human erythropoietin (r-HuEPO, epoetin alfa) increased haemo-
globin (Hb) levels and subsequently ameliorated anaemia in
cancer patients. Moreover, in the studies that evaluated QoL, epoe-
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activity levels to an overall improvement in QoL (Abels, 1992; Leit-
geb et al, 1994; Glaspy et al, 1997; Demetri et al, 1998; Gabrilove et
al, 2001). Epoetin alfa has also been shown to cross the blood–
brain barrier and exhibit neuroprotective effects in preclinical
studies (Brines et al, 2000; Cerami et al, 2001); and clinical trials
in anaemic patients with chronic renal failure suggest that correc-
tion of anaemia with epoetin alfa improves brain and cognitive
function (Marsh et al, 1991; Pickett et al, 1999).
The results from a study evaluating the effects of epoetin alfa on
transfusion requirements and haematopoietic response, together
with a univariate analysis of the study’s QoL data, have been
published in detail elsewhere (Littlewood et al, 2001). However,
univariate analysis did not take into account possible between-
group differences in factors that could inﬂuence QoL outcome.
Therefore, to assess more precisely the effects of epoetin alfa treat-
ment on QoL, these data were additionally examined by a priori-
planned multiple linear regression analysis, which controlled for
disease progression and other possibly confounding variables
(e.g., demographic and baseline clinical characteristics). In this
study, we present the ﬁndings of the multiple linear regression
analysis and explore more fully the relationship between Hb level
and QoL. We also take this opportunity to describe the design
and results from this study more fully than was possible in the
article by Littlewood et al (2001).
PATIENTS AND METHODS
Patients and study design
The design of the study has been described previously (Littlewood
et al, 2001). Brieﬂy, the randomised, double-blind, placebo-
controlled trial was conducted in 15 countries at 73 sites with
375 patients (intent-to-treat (ITT) population). The QoL analysis
population comprised those ITT patients who had both a baseline
and at least 1 follow-up QoL assessment.
To be enrolled, patients were required to have a conﬁrmed diag-
nosis of solid or non-myeloid haematologic malignancy for which
they may or may not have been receiving non-platinum
chemotherapy, but were scheduled to receive (an additional) 12–
24 weeks (3–6 cycles) of such therapy. Only patients receiving
non-platinum regimens could be included in this phase III study
because epoetin alfa was already licensed worldwide for use in
patients receiving platinum regimens. In addition, at screening
(approximately 1 week prior to randomisation to study drug),
patients were required to have Hb levels 410.5 g dL
71, or levels
410.5 g dL
71 but 412 g dL
71 following a 51.5-g dL
71 decrease
in Hb per cycle or month since starting chemotherapy. Patients
with acute leukaemia or myeloid malignancies were excluded, as
were those with untreated iron, folate, or vitamin B12 deﬁciency.
Also excluded were patients who had acute major infection or
bleeding within 1 month, radiation therapy or allogeneic blood
transfusion within 2 weeks, or surgery or acute major illness within
1 week prior to study entry. All patients provided written informed
consent before undergoing any study-related procedures.
Patients were stratiﬁed by tumour type (solid or haematologic)
and Hb level (410.5 g dL
71,o r410.5 but 412 g dL
71)a t
screening. They were randomised in a 2:1 ratio, balanced by using
permuted blocks, to receive epoetin alfa 150–300 IU kg
71 three
times per week or matching placebo by subcutaneous injection.
(Outside of the United States, epoetin alfa is manufactured by
Ortho Biologics, LLC and distributed and marketed as EPREX1
or ERYPO1 by Ortho Biotech and Janssen-Cilag. In the United
States, PROCRIT1 (epoetin alfa) is manufactured by Amgen
Inc. and distributed and marketed by Ortho Biotech Products,
L.P.) Study treatment (i.e., epoetin alfa or placebo) was adminis-
tered for the duration of the study, a maximum of 28 weeks.
Study duration included 12–24 weeks (3–6 cycles) of chemother-
apy and a 4-week period when study treatment continued after the
last dose of chemotherapy.
The sample size for the trial was determined in consideration of
ﬁnding a signiﬁcant effect for the primary efﬁcacy endpoint (trans-
fusions after the ﬁrst 28 days on-study). Speciﬁcally, the sample size
calculation was based on detecting an odds ratio of 2 between
success and treatment, where success is deﬁned as the absence of
any transfusion after the end of the ﬁrst 4 weeks of treatment.
Given a power of 90%, a signiﬁcance level of .05 (one-sided),
and based on the Cochran-Mantel-Haenszel test, the sample size
needed was a priori calculated as 120 in the placebo arm and 240
in the epoetin alfa arm, resulting in a total sample size of 360
(patients randomised to epoetin alfa and placebo in a ratio of 2:1).
Evaluation of quality of life
The QoL hypothesis for this study was that administration of epoe-
tin alfa would improve QoL relative to placebo due to treatment-
induced improvements in Hb levels. Clinical efﬁcacy endpoints
included the proportion of patients transfused after the ﬁrst 4
weeks of anaemia treatment (primary endpoint) and change in
Hb level from baseline to last available value (secondary endpoint).
Change in QoL from baseline to last available assessment was also a
secondary efﬁcacy endpoint. The effects of epoetin alfa on QoL
were assessed using three patient-rated QoL instruments: subscales
of the Functional Assessment of Cancer Therapy-Anaemia (FACT-
An), the Cancer Linear Analogue Scale (CLAS, also known as Line-
ar Analogue Scale Assessment, or LASA), and the Medical
Outcomes Study Short Form-36 (SF-36). The FACT-An is a 47-
item, cancer-speciﬁc questionnaire comprising a core 27-item
general questionnaire (FACT-G Total) that measures physical,
social/family, emotional, and functional well-being, and an addi-
tional 20-item anaemia questionnaire that assesses the impact of
fatigue (13 items, fatigue subscale (FACT-An Fatigue subscale))
and anaemia (seven items, anaemia subscale (FACT-An Anaemia
subscale)). The CLAS, another cancer-speciﬁc instrument, consists
of three QoL visual analogue scales that measure energy level, abil-
ity to do daily activities, and overall QoL using a 100-mm scale.
The SF-36 is a general health-assessment instrument that provides
scores for eight QoL dimensions as well as summary scores for two
derived measures (Physical Component Summary and Mental
Component Summary (PCS and MCS, respectively)). Possible
scores from the FACT-G Total scale range from 0 to 108; for the
FACT-An Fatigue subscale, scores range from 0 to 52; and for
the three CLAS items scores range from 0 to 100. The SF-36
PCS and MCS scales have no meaningful lower or upper bounds,
but are standardised to have a mean of 50 and a standard deviation
of 10 points based upon a representative sample from the United
States population. The procedure for deriving the standardised
PCS and MCS scores has been cross-culturally validated by the
instrument developers (Bullinger et al, 1998). Higher scores repre-
sent better QoL in every case.
Five QoL scales (FACT-G Total, FACT-An Fatigue subscale
(Cella, 1997; Demetri et al, 1998), CLAS:Energy, CLAS:Ability
to Do Daily Activities, CLAS:Overall QoL (Cella, 1997; Glaspy et
al, 1997; Demetri et al, 1998)) have demonstrated sensitivity to
Hb levels and were therefore designated a priori as the primary
QoL efﬁcacy endpoints for analyses of the effects of epoetin alfa.
The SF-36 PCS and MCS scales were additionally designated as
primary QoL endpoints for analyses, and were included as general
measures of QoL.
Patients self-administered the three QoL questionnaires as a
single packet a maximum of four times during the study: (1)
pretreatment (at the time of randomisation to either epoetin alfa
or placebo); (2) before the start of the second on-study chemother-
apy cycle for patients on a cyclic chemotherapy regimen (or
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chemotherapy cycle (or approximately week 16); and (4) at study
completion (within 5 days of study completion or at the time of
early withdrawal) (Figure 1). QoL questionnaires were ﬁlled out
by the patients at the beginning of the relevant study visits, before
any other tests, procedures, or consultations. In this way, reported
QoL was masked with respect to current clinical status. No provi-
sions were made for caregivers or other proxies to ﬁll out the QoL
questionnaires in cases where the patients were unable to do so.
Each patient enrolled in the study was expected to complete the
QoL assessments (where available in his or her language).
Even if a patient received more than six cycles of chemotherapy,
the study was scheduled to end at a maximum of 28 weeks.
Patients were enrolled into the study if they were expected to
undergo a minimum of three and a maximum of six (additional)
cycles of chemotherapy. However, chemotherapy may have been
discontinued earlier as a result of disease progression or toxicity
of the chemotherapeutic regimen. Therefore, some patients who
did not begin a second cycle of chemotherapy, and thus did not
self-administer the ﬁrst follow-up QoL assessment, may still have
completed the epoetin alfa study. In such cases, patients were asked
to complete the QoL assessment scheduled for study completion.
Because patients could be enrolled with a variable number of
expected chemotherapy cycles, and because those cycles could be
of varying durations, the timing of QoL assessments could not
be standardised to speciﬁc days or weeks in the study. The actual
timing of the QoL assessments that resulted from this study design
is illustrated in Figure 2, where the vertical axis represents patients
(sorted by days in the study) and the horizontal axis represents
study duration. Missing assessments were not imputed.
Statistical methods
For all analyses, QoL change scores were calculated by subtracting
the baseline score from the score obtained at the last available
assessment. Changes in QoL data were examined by univariate
and multiple linear regression analyses. Univariate analysis methods
have been published elsewhere (Littlewood et al, 2001). Multiple
linear regression analyses, which were planned a priori, were
performed because previous studies indicated that disease progres-
sion has a profound effect on QoL scores at follow-up (Demetri et
al, 1998). Therefore, including disease progression and other
confounding factors in each model elucidates pure treatment effect
on QoL by adjusting for the effects of these factors. These multiple
linear regression analyses were performed as a validation test for
the originally published univariate analyses.
For the multiple linear regression analyses, separate analyses of
covariance models were estimated for each of the seven primary
QoL endpoints using the SAS General Linear Model (GLM) proce-
dure (SAS Institute, Inc., Cary, NC, USA). In all models, the QoL
change score was the dependent variable. Independent variables
included treatment with epoetin alfa, disease progression, treatment
interaction with disease progression, and several selected demo-
graphic and clinical variables (age, sex, race, baseline Hb level,
baseline neutrophil count, baseline reticulocyte count, baseline
erythropoietin level, prestudy transfusion dependence, and tumour
type (solid or haematologic)). Variables representing treatment
with epoetin alfa and disease progression and its interaction with
treatment were included in every model. Response to chemother-
apy was collected at study termination or early withdrawal. A
progressive disease ﬂag was constructed from the chemotherapy
response values by setting the ﬂag to one if the response was
Progressive Disease (increase in estimated tumour mass by
525% or appearance of new lesion), and by setting the ﬂag to zero
otherwise. Patients who were not assessed were categorised as
‘Unknown’ (i.e., not progressive disease). All other independent
variables were retained in the model if they were signiﬁcant at or
below the 10% level. Mean QoL change was estimated for each
treatment group from the regression parameter estimates using
the Least Squares Means (LSM) method (Searle et al, 1980). T
statistics were then generated to test for differences in mean change
scores between the treatment groups. All signiﬁcance tests were
two-sided, with the alpha level set at 0.05, adjusting for multiple
comparisons using a sequentially rejective version of the Bonferroni
procedure (Hochberg, 1988).
The LSM analysis was performed over the entire QoL analysis
population adjusted for all covariates, including disease progres-
sion. From this analysis, the overall mean changes in QoL for
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Figure 2 Timing of QoL assessments. Each symbol represents a QoL as-
sessment for a patient at the speciﬁed time in the study. The three separate
symbols represent the last assessment for a patient who withdrew early
(star), the last assessment for a completer (closed circle), or a continuing
assessment (open circle).
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progression and its interaction with treatment were included in
each multiple linear regression model, LSMs of adjusted QoL
change scores could also be generalised to two separate patient
populations: a population containing only patients exhibiting
disease progression and another containing only patients not exhi-
biting disease progression (i.e., stable, partial, or complete
responders to chemotherapy). It should be emphasised that the
LSM analysis of patients exhibiting disease progression was not a
subgroup analysis; it was an estimate resulting from the regression
parameters calculated over all study patients in the entire QoL
cohort. The results of such an analysis can be interpreted as
predicting the treatment-related QoL beneﬁt that would be
expected for a hypothetical patient exhibiting disease progression
or for a hypothetical patient not exhibiting disease progression.
Of course, in practice, clinicians cannot generally predict which
patients will progress. However, because disease progression has
such a detrimental effect upon patient QoL, we have explicitly
included that possibility in our model speciﬁcation. This addresses
the criticism recently made by Bottomley et al that most QoL
papers investigating the effects of epoetin alfa do not take tumour
response into account (Bottomley et al, 2002).
Given the underlying QoL hypothesis that administration of
epoetin alfa would improve QoL relative to placebo due to treat-
ment-induced improvements in Hb levels, Pearson correlation
coefﬁcients were calculated to assess the relationship between base-
line Hb level and QoL (cross-sectional correlation), and between
change in Hb level and change in score for each primary QoL
endpoint (longitudinal correlations). P values associated with these
correlation coefﬁcients were also adjusted for multiple comparisons
using the sequentially rejective Bonferroni procedure.
RESULTS
Table 1 presents the QoL assessments expected at baseline and
follow-up based upon the study design and timing of discontinuing
patients. There was a minimal amount of avoidable QoL data miss-
ing in this trial due to administrative or logistical reasons
(approximately 6.5%, shown as missing CLAS data in Table 1).
As seen in the last column of Table 1, 1076 of 1151 QoL assess-
ments expected were available. In the context of clinical studies
in oncology, this represents a very low rate of avoidable missing
data (Bernhard et al, 1998).
Generally, there was a very low rate of missing QoL items (as
opposed to multi-item scales), given the completion of an assess-
ment (Table 2). Over the seven QoL scales chosen a priori for
analysis, there was approximately a 2.45% rate of missing items.
The FACT-An and the SF-36 scales can be scored in the presence
of some level of missing items, but those multi-item scales do
mandate a requisite number of non-missing items (usually 50%
non-missing). Thus, the missing scale rates for the seven QoL
scales chosen a priori for analysis are also presented in Table 2.
As the table shows, there was a 2.09% missing scale rate for these
seven scales combined. Because the SF-36 PCS and MCS are
derived from the same set of items, the percent missing for these
two scales is equivalent.
In addition to the data missing due to administrative or logisti-
cal reasons, 54 patients in the ITT population had no FACT or SF-
36 data owing to unavailability of these questionnaires in some
languages (i.e., Czech, Greek, Hungarian, Polish), and an addi-
tional 23 were missing those data for other reasons. The CLAS
questionnaire was available and administered in the languages
named above, as well as in Dutch, English, French, German,
Italian, and Portuguese, but 39 patients had missing CLAS data
for non-language-related reasons. Therefore, a total of 298
(79.5%) and 336 (89.6%) patients from the ITT population were
included in the FACT and CLAS analyses, respectively. The
numbers of patients from each country whose FACT or CLAS data
were available for analysis are shown in Table 3. Figure 3 is a ﬂow
diagram, recommended for use by the CONSORT statement, that
displays patients’ progress through the phases of the trial (Moher
et al, 2001).
Baseline characteristics
Baseline characteristics of the QoL population by covariate are
summarised in Table 4. These characteristics were generally
comparable between the epoetin alfa- and placebo-treated patients.
Ninety-two per cent of patients in each treatment group had begun
chemotherapy within 3 months of the beginning of the study
(Littlewood et al, 2001). Eligibility for the study was limited to
patients whose Hb was 412 g dL
71 at screening; however, because
some patients may have received transfusions or ceased chemother-
apy treatment following screening, their Hb may have risen higher
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Table 1 Per cent missing QoL (CLAS) assessments
Baseline
a First follow-up
b Second follow-up
c Third follow-up
d Total follow-up
QoL assessments expected 375 351 294 132 1152
Died without assessments 1 0 0 0 1
Net assessments expected 374 (100%) 351 (100%) 294 (100%) 132 (100%) 1151 (100%)
Missing assessments 18 (4.8%) 29 (8.3%) 24 (8.2%) 4 (3.0%) 75 (6.5%)
Discontinuations 16 30 62 20 128
Died with assessments 6 18 6 0 30
Completers 1 9 94 112 216
Remainder of assessments 351 294 132 0
Assessments available 356 (95.2%) 322 (91.7%) 270 (91.8%) 128 (97.0%) 1076 (93.5%)
aBefore ﬁrst on-study chemotherapy cycle;
bWithin +3 days of start of second on-study chemotherapy cycle;
cWithin +3 days of start of ﬁfth on-study
chemotherapy cycle;
dAt study completion/withdrawal.
Table 2 Rates of missing items and scales across QoL assessments
Scale Per cent missing items Per cent missing scales
FACT-G total 3.87 3.52
FACT-An Fatigue subscale 1.58 1.14
CLAS: Energy 0.00 0.00
CLAS: Daily activities 0.09 0.09
CLAS: Overall QoL 0.18 0.18
SF-36 PCS 1.86 5.30
SF-36 MCS 1.86 5.30
Total 2.45 2.09
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71 by the time their baseline measurements were
assessed. These patients were included in the study and in the
ITT analyses.
Transfusion needs and haematopoietic response
Fewer epoetin alfa-treated patients than placebo-treated patients in
the ITT population were transfused after day 28 (24.7% vs 39.5%,
P50.01, Wald’s w
2 test from logistic model correcting for tumour
type and Hb stratum) (Littlewood et al, 2001). (For this analysis,
patients on study 28 days or less were counted as transfused, that
is, as failures.) Patients treated with epoetin alfa had a signiﬁcantly
greater increase in mean (+s.d.) Hb level than did those treated
with placebo (2.2+2.18 g dL
71 vs 0.5+1.79 g dL
71, P50.01, t-
test). (Transfusion-related changes in Hb level were included in
the calculation of mean change.) This pattern was observed regard-
less of tumour type (solid vs haematologic) or Hb stratum
(Littlewood et al, 2001).
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Table 3 QoL population by country of enrolment
FACT-An or
ITT FACT-An CLAS CLAS
Country n (%) n (% of ITT) n (% of ITT) n (% of ITT)
Germany 77 (20.53) 72 (93.51) 72 (93.51) 72 (93.51)
The Netherlands 60 (16.00) 54 (90.00) 51 (85.00) 54 (90.00)
Great Britain/Ireland 42 (11.20) 40 (95.24) 38 (90.48) 40 (95.24)
Belgium/Luxembourg 36 (9.60) 28 (77.78) 25 (69.44) 28 (77.78)
Italy 30 (8.00) 30 (100.00) 30 (100.00) 30 (100.00)
South Africa 25 (6.66) 25 (100.00) 21 (84.00) 25 (100.00)
France 21 (5.60) 19 (90.48) 18 (85.71) 19 (90.48)
Switzerland 16 (4.26) 16 (100.00) 16 (100.00) 16 (100.00)
Poland 15 (4.00) 0 (0.00) 15 (100.00) 15 (100.00)
Portugal 14 (3.73) 14 (100.00) 14 (100.00) 14 (100.00)
Greece 17 (4.53) 0 (0.00) 14 (82.35) 14 (82.35)
Hungary 13 (3.46) 0 (0.00) 13 (100.00) 13 (100.00)
Czech Republic 9 (2.40) 0 (0.00) 9 (100.00) 9 (100.00)
TOTAL 375 (100.00) 298 (79.47) 336 (89.60) 349 (93.07)
Randomised 2 : 1 (n = 375)
Allocated to epoetin alfa (n = 251)
Received allocated intervention (n = 251)
Did not receive allocated intervention (n = 0)
Discontinued intervention (n = 91)
Reason: Death (n = 17)
               Patient choice (n = 18)
               Disease progression
               (n = 19)
               Other (n = 37)
Lost to follow-up (n = 5)
Included in CLAS
Analysis (n = 228)
Excluded from CLAS
analysis (n = 23)
              Reason: Translation not
              available (n = 0)
              Baseline or follow-up
              assessment missing
              (n = 23)
              Died before baseline
              assessment: (n = 0)
Included in FACT-An/SF-36
Analysis (n = 205)
Excluded from FACT-An/SF-36
analysis (n = 46)
              Reason: Translation not
              available (n = 35)
              Baseline or follow-up
              assessment missing
              (n = 11)
              Died before baseline
              assessment: (n = 0)
Included in CLAS analysis
(n = 108)
Excluded from CLAS
analysis (n = 16)
              Reason: Translation not
              available (n = 0)
              Baseline or follow-up
              assessment missing
              (n = 15)
              Died before baseline
              assessment: (n = 1)
Included in FACT-An/SF-36
Analysis (n = 93)
Excluded from FACT-An/SF-36
analysis (n = 31)
              Reason: Translation not
              available (n = 18)
              Baseline or follow-up
              CLAS assessment
              missing (n = 12)
              Died before baseline
              assessment: (n = 1)
Discontinued intervention (n = 63)
Reason: Death (n = 14)
               Patient choice (n = 20)
               Disease progression
               (n = 11)
               Other (n = 18)
Lost to follow-up (n = 0)
Allocated to placebo (n = 124)
Received allocated intervention (n = 124)
Did not receive allocated intervention (n = 0)
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Figure 3 Flow diagram of the patients’ progress through the phases of the trial.
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The multiple linear regression models and parameter values used to
generate LSMs for each of the analyses in this report are presented
in Table 5. Table 6 presents LSM estimates for the seven primary
QoL endpoints for the overall analysis and by disease progression
status. Results of both the univariate and multiple linear regression
analyses of QoL change scores for the two treatment groups are
displayed in Figures 4, 5, and 6 with the previously published
(Littlewood et al, 2001) univariate analyses QoL results included
as a reference.
After adjusting for possible differences in demographic and clin-
ical characteristics between the treatment groups, results of the
multiple linear regression analyses conﬁrmed the results of the
univariate analyses. All within-group mean change scores for the
epoetin alfa group were again positive (Figures 4–6). Further, mean
changes for all seven of these scores were statistically signiﬁcant
(range, P50.01 to P50.05) (Table 6). In contrast, within-group
mean change scores for the placebo group were negative, except
for the SF-36 MCS and PCS (Figures 4–6). For the overall QoL
population, between-group comparisons of the LSM QoL change
scores showed statistically signiﬁcant differences favouring epoetin
alfa for all ﬁve cancer-speciﬁc scales (range, P=0.01 to P=0.04)
but not for the two SF-36 scales (Figures 4–6, Table 6). However,
the two SF-36 scales showed no evidence of deterioration in overall
physical or mental QoL for patients treated with epoetin alfa.
As estimated by the multiple linear regression model, a hypothe-
tical patient treated with epoetin alfa and exhibiting no disease
progression can expect signiﬁcant beneﬁt as measured by the
FACT-An Fatigue subscale and all three CLAS scales. However, a
hypothetical patient exhibiting disease progression (in this study,
approximately 28% of the QoL population experienced disease
progression) could expect no beneﬁt in these measures as based
upon the multiple linear regression results (Table 6). These results
can be seen as validating the sensitivity of the QoL instruments
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Figure 4 QoL mean change scores by treatment group: results of univariate (Littlewood et al, 2001) and multiple linear regression analyses* (FACT-G
Total scale and FACT-Fatigue Subscale). *P values adjusted for multiple comparisons (sequentially rejective Bonferroni procedure).
Table 4 Baseline characteristics by covariate (QoL population)
Epoetin Alfa Placebo
Covariate (n=238) (n=111)
Sex, n (%)
Female 158 (66) 77 (69)
Male 80 (34) 34 (31)
Age (years)
Mean+s.d. 58.1+14.2 59.2+14.3
Range 18.7–84.9 21.1–88.6
Race, n (%)
White 230 (97) 106 (96)
Asian 1 (51) 3 (3)
Black 4 (2) 0 (0)
Other 3 (1) 2 (2)
Haemoglobin (g dl
71)
Mean+s.d. 9.9+1.1 9.8+1.1
Median 10.0 9.7
Range 5.9–14.3 6.6–12.7
Tumour type, n (%)
Solid 127 (53) 60 (54)
Haematologic 111 (47) 51 (46)
Prestudy transfusion(s), n (%) 68 (29) 38 (34)
Neutrophil count, %
Mean+s.d. 61.5+20.9 62.1+20.4
Median 66.0 67.4
Range 1.0–94.5 2.0–96.0
Reticulocyte count, %
Mean+s.d. 2.2+1.3 2.4+1.5
Median 2.0 2.1
Range 0.0–7.5 0.0–11.5
Serum erythropoietin, mU mL
71
Mean+s.d. 102.9+196.8 94.1+108.0
Median 49.0 50.0
Range 10–1890 10–597
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of cancer patients (i.e., a population containing both responders
and non-responders to cancer treatment), a signiﬁcant degradation
in patient QoL would generally be associated with signiﬁcant
disease progression, regardless of cancer-related anaemia treatment.
Correlation between haemoglobin and quality of life
Correlation analyses were performed to examine the relationship
between Hb level and QoL (Table 7). Positive cross-sectional
correlations were found for every scale except the SF-36 MCS
scale. Slightly stronger longitudinal correlations were found using
all seven primary QoL scales; all P values were signiﬁcant (range,
P50.01 to P=0.03). Figure 7 demonstrates the relationship
between Hb and QoL over time by showing biweekly Hb levels
(Littlewood et al, 2001) and monthly CLAS Energy levels. While
the QoL assessments were not designed in this study to yield
monthly mean scores and no analysis of monthly mean scores
was conducted or reported in this study, this graph does help
to visualise the longitudinal relationship between Hb and QoL.
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Table 5 QoL change score multiple linear regression parameter estimates
QoL measures coefﬁcient estimates (s.e.)
FACT-G FACT-An
Covariates Total Fatigue Energy Activities Overall PCS MCS
Sample Size n=253 n=266 n=312 n=284 n=311 n=237 n=225
Epoetin alfa n=175 n=185 n=215 n=196 n=215 n=160 n=153
Placebo n=78 n=81 n=97 n=88 n=96 n=77 n=72
R
2 0.23 0.19 0.15 0.20 0.17 0.25 0.11
Intercept 6.37 7.31 73.72 72.98
b 70.84 70.32 20.79
b
(8.42) (7.94) (16.10) (21.21) (15.76) (3.46) (7.16)
Epoetin alfa 4.58
a 6.64
b 15.05
b 13.95
b 14.50
b 2.92
a 2.03
(2.13) (1.82) (4.07) (4.65) (4.01) (1.27) (1.87)
Disease progression 79.57
b 73.05 77.68 712.09 74.95 73.33 74.13
(3.14) (2.68) (5.78) (6.47) (5.67) (1.82) (2.65)
Epoetin alfa * disease 70.30 78.00
a 715.50
a 714.44 720.61
b 75.97
b 71.77
progression (3.80) (3.28) (7.16) (8.03) (7.02) (2.27) (3.33)
Caucasian 12.88
b 10.66
b 23.68
b 17.23 29.04
b 9.84
b –
(4.00) (3.50) (8.02) (8.97) (7.85) (2.35)
Age – 70.09 – 70.24 – 70.10
b –
(0.05) (0.12) (0.04)
Female – – – – – 71.89 –
(1.08)
Baseline haemoglobin 71.28 71.29
a 72.05 75.64
b 73.01
a – 71.63
b
(0.71) (0.62) (1.37) (1.61) (1.34) (0.69)
Baseline neutrophil count – – – 70.26
b –––
(0.09)
Baseline reticulocyte count 71.18
a –––– 70.73
a –
(0.59) (0.36)
Baseline endogenous EPO – – – 70.02
a –– 70.01
a
(0.01) (0.005)
Pre-study transfusion – – – – – 2.62
a –
dependent (1.06)
Solid tumour group 75.71
b –––– – 73.76
a
(1.68) (1.46)
s.e.=standard error of the mean, 95% conﬁdence interval.
aP40.05;
bP40.01.
Table 6 Regression analyses: least squares means, last assessment change scores
Epoetin alfa Placebo Difference
Nom. Adj. Nom. Adj. Nom. Adj.
QoL Scale Mean s.e. P value P value
a Mean s.e. P value P value
a Mean s.e. P value P value
a
Overall
FACT-G Total 2.01 0.98 0.04 0.04 72.48 1.47 0.09 0.66 4.49 1.77 0.01 0.04
FACT-An Fatigue subscale 2.70 0.84 50.01 50.01 71.70 1.27 0.18 0.90 4.40 1.52 50.01 0.02
CLAS:Energy 7.17 1.86 50.01 50.01 73.40 2.80 0.22 0.90 10.57 3.36 50.01 0.01
CLAS:Daily Activities 7.78 2.09 50.01 50.01 71.96 3.16 0.54 0.96 9.74 3.80 0.01 0.04
CLAS:Overall QoL 4.46 1.82 0.02 0.04 74.10 2.76 0.14 0.83 8.56 3.31 0.01 0.04
SF-36:PCS 1.27 0.60 0.04 0.04 0.05 0.87 0.96 0.96 1.22 1.06 0.25 0.33
SF-36:MCS 1.88 0.87 0.03 0.04 0.35 1.28 0.78 0.96 1.53 1.55 0.33 0.33
No disease progression
b
FACT-G Total 4.83 1.14 50.01 50.01 0.25 1.81 0.89 0.89 4.58 2.13 0.03 0.06
FACT-An Fatigue subscale 5.79 0.97 50.01 50.01 70.85 1.54 0.58 0.89 6.64 1.82 50.01 50.01
CLAS:Energy 13.86 2.16 50.01 50.01 71.19 3.45 0.73 0.89 15.05 4.07 50.01 50.01
CLAS:Daily Activities 15.53 2.41 50.01 50.01 1.58 3.98 0.69 0.89 13.95 4.65 50.01 50.01
CLAS:Overall QoL 11.83 2.11 50.01 50.01 72.67 3.41 0.43 0.89 14.50 4.01 50.01 50.01
SF-36:PCS 3.92 0.69 50.01 50.01 1.00 1.07 0.35 0.89 2.92 1.27 0.02 0.06
SF-36:MCS 3.55 0.99 50.01 50.01 1.52 1.60 0.34 0.89 2.03 1.88 0.28 0.28
Disease progression
b
FACT-G Total 75.04 1.98 0.01 0.02 79.31 2.53 50.01 50.01 4.27 3.16 0.18 0.94
FACT-An Fatigue subscale 75.26 1.64 50.01 50.01 73.90 2.20 0.08 0.21 71.36 2.74 0.62 0.94
CLAS:Energy 79.32 3.67 0.01 0.02 78.87 4.64 0.06 0.21 70.45 5.91 0.94 0.94
CLAS:Daily Activities 710.99 4.19 50.01 0.02 710.51 5.06 0.04 0.21 70.48 6.49 0.94 0.94
CLAS:Overall QoL 713.73 3.59 50.01 50.01 77.62 4.54 0.09 0.21 76.11 5.79 0.29 0.94
SF-36:PCS 75.38 1.20 50.01 50.01 72.33 1.47 0.11 0.21 73.05 1.89 0.11 0.75
SF-36:MCS 72.36 1.82 0.20 0.20 72.61 2.09 0.21 0.21 0.25 2.71 0.93 0.94
Nom, nominal; Adj, adjusted.
aAdjusted using a sequentially rejective Bonferroni procedure;
bAs estimated from multiple linear regression across all patients.
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using 28-day windows for months, with the last observation
carried forward for missing values and dropouts. It is possible that
the decline in QoL seen in the placebo arm, despite relatively
stable but low Hb levels, may suggest that long-term anaemia
has a cumulative effect on QoL, especially during chemotherapy.
The signiﬁcant correlations seen in Table 7, and QoL response
to Hb shown in Figure 7, suggest that the administration of epoe-
tin alfa in this patient population improves health-related QoL,
which is associated with treatment-induced improvements in Hb
levels.
Safety
Information regarding adverse events has been reported in detail
elsewhere (Littlewood et al, 2001). Epoetin alfa was well tolerated,
and the overall incidence of adverse events and the incidence of
individual adverse events were generally similar between the two
treatment groups.
DISCUSSION
Assessment of QoL has now become a standard, and in some cases
mandatory, endpoint in oncology clinical trials and studies. This
increased focus on QoL as a therapeutic outcome is being driven
by advances made in cancer treatment and management over the
last few decades. Earlier detection of malignancies and widespread
availability of cancer screening programmes have increased the
possibility of successful treatment and recovery, although often at
the cost of functional ability and physical, emotional/mental, or
social well-being. Also, more intense treatment strategies are being
employed with the potential for greater toxicity and associated
negative impact on QoL. Determination of the QoL outcome for
any potential therapy, whether cancer-speciﬁc or supportive, is
therefore essential for evaluating comparative treatments as well
as making decisions about future treatment or palliative care
(Cella, 1997). The primary therapeutic endpoints of concern to
the clinical scientist may be very different from those of patients
and, consequently, the value placed on gaining relief from symp-
toms may differ also. Thus, to make informed decisions about
the beneﬁts of supportive treatments that have cost implications,
both doctors and their patients need the information gained from
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Table 7 Correlation between haemoglobin level and QoL scores
Correlation Nominal P Value
QoL Scale n Coefﬁcient P Value (adjusted
a)
Cross-sectional
FACT-G Total 288 0.26 50.01 50.01
FACT-Fatigue subscale 293 0.16 50.01 0.02
CLAS:Energy 336 0.14 0.01 0.03
CLAS:Daily Activities 336 0.17 50.01 0.01
CLAS:Overall QoL 335 0.18 50.01 0.01
SF-36:PCS 285 0.14 0.02 0.03
SF-36:MCS 285 0.09 0.15 0.15
Longitudinal
FACT-G Total 266 0.26 50.01 50.01
FACT-An Fatigue subscale 273 0.29 50.01 50.01
CLAS:Energy 322 0.30 50.01 50.01
CLAS:Daily Activities 322 0.34 50.01 50.01
CLAS:Overall QoL 321 0.33 50.01 50.01
SF-36:PCS 250 0.26 50.01 50.01
SF-36:MCS 250 0.14 0.03 0.03
aBased on Pearson’s correlation coefﬁcient, with P value adjusted for multiple
comparisons (sequentially rejective Bonferroni procedure).
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evaluation.
The FACT-G Total, FACT-An Fatigue subscale, CLAS, and SF-
36: PCS and MCS scales were chosen as primary QoL endpoints
to assess the effects of epoetin alfa on QoL in the present study.
The FACT-G Total, FACT-An Fatigue subscale, and CLAS were
considered especially appropriate for this purpose as they are
cancer-speciﬁc, Hb-sensitive, and easily completed by patients.
The CLAS, in addition, had been used frequently in previous trials
of epoetin alfa and, at the time this study was initiated, was more
widely available than the FACT scales in the languages of the parti-
cipating countries (10 vs six languages). Also, its use could facilitate
comparisons between the results of this study and previous trials.
The SF-36 is not cancer-speciﬁc but was included as a general
measure to ensure that there were no unexpected adverse conse-
quences of epoetin alfa therapy affecting overall QoL.
To clarify the effect of epoetin alfa on QoL, beyond that originally
reported based upon univariate analyses (Littlewood et al, 2001), a
multiple linear regression analysis was performed that took into
account tumour progression as well as many other possibly
confounding variables (e.g., age, sex, baseline Hb). As in the univari-
ate analysis, the P values were adjusted to account for multiple
comparisons. The results of this analysis conﬁrmed the advantage
of epoetin alfa over placebo, as demonstrated in the univariate analy-
sis, with signiﬁcant differences again noted for all cancer-speciﬁc
scales. While the generality of the two SF-36 summary scales reduced
their ability to discriminate between groups in this analysis, the posi-
tive (though non-signiﬁcant) SF-36 changes favouring epoetin alfa
strongly suggest that there were no general trends in unforeseen
detrimental effects on QoL from epoetin alfa treatment using an
instrument that casts a wide net for functional and well-being
domains. In fact, it should be noted that the within-group analysis
shows a positive and statistically signiﬁcant change in the two SF-
36 scales for the epoetin alfa group, but no corresponding signiﬁcant
change for the placebo group.
While only 2–3% of the patients included in the current report
were non-Caucasian, race was included as a covariate because it has
historically been a strong predictor of QoL and is customarily
included in multiple linear regression analyses of treatment effect
on QoL. The variable’s highly signiﬁcant parameter estimates,
despite the low number of non-Caucasian patients included in
the study, indicates that race may be an important predictor of
patient QoL. For this reason, and to maintain consistency with
the main body of QoL research, we decided to retain race in our
regressions.
A possible limitation of this analysis is the focus upon the QoL
change from baseline to the last available assessment. Analyses
incorporating change scores derived in this manner may be affected
by bias across treatment arms. For example, patients in one treat-
ment arm may stop early due to anaemia (and thus a low QoL)
whereas in the other arm patients may stop due to other reasons
(and perhaps their last assessment will be a normal QoL). We
chose to deﬁne the QoL change score in this manner to remain
consistent with the results reported in Littlewood et al (2001) for
both the QoL and the other clinical measures. However, a separate
sensitivity analysis was conducted that incorporated the longitudi-
nal nature of the Littlewood et al (2001) data. This sensitivity
analysis included all available data from each patient and also
adjusted for censored assessments (Fairclough and Gagnon,
2000). Compared with the baseline-to-last assessment analysis
described in this study, the sensitivity analysis found that the
between-group differences remained similar between the two analy-
tic techniques.
While the results reported here are statistically signiﬁcant, the
question remains whether they are clinically relevant. By examining
Figures 4 and 5, one can see a between-group difference of 4 to 5
points in FACT-G Total and FACT-An Fatigue subscale change
scores and a between-group difference of 8.5–10.6 points for the
three CLAS scales. The question of the clinical relevance of these
changes can be partially answered by the results of two recent
analyses. An analysis based on the Littlewood et al study compared
the FACT-An and CLAS score changes of improved and stable
patients; differences in corresponding QoL scores were considered
to be the minimally important differences (MIDs) (Patrick et al,
2000). For the FACT-G Total and Fact-An Fatigue subscale, the
MIDs were 2.25 and 4.23, respectively. For the CLAS scales, the
MIDs ranged from 8.98 to 10.26. The between-group differences
observed from the multivariate analyses exceeded the MIDs for
all scales except the CLAS Overall QoL. A separate analysis
compared the FACT-An scores from the Littlewood et al (2001)
trial with scores from a demographically representative United
States sample (Nortier et al, 2001). The analysis found that the
between-group QoL advantage seen in epoetin alfa-treated patients
represented 95% and 51% of the deﬁcit from normative scores
seen at baseline for the FACT-G Total and FACT-An Fatigue
subscale, respectively. Based on the conclusions of these analyses,
the results for the cancer-speciﬁc scales seen in the clinical trial
appear not only to be statistically signiﬁcant, but also clinically
relevant.
Due to space limitations and, often, trial design, QoL results (if
they are published at all) are usually presented in a fashion similar
to that used for physiologic endpoints (i.e., a simple statistical
comparison of ITT groups). The current study is given to rigorous
analysis including multiple linear regression on over a dozen covari-
ates, consideration of patterns of missing data, and further
interpretation of the robustness of the results based upon these
analyses. Further, the ﬁnding of a positive within-group epoetin alfa
treatment effect on cancer-speciﬁc QoL is corroborated by several
randomised placebo-controlled and open-label studies (Abels,
1992; Glaspy et al, 1997; Demetri et al, 1998; Gabrilove et al,
2001). In the earliest of these studies (Abels, 1992), QoL was
assessed in a series of placebo-controlled trials conducted in three
different patient populations: patients receiving no chemotherapy,
patients receiving non-cisplatin-containing chemotherapy, and
patients receiving cisplatin-containing chemotherapy. QoL was eval-
uated by means of visual analogue scales that measured energy level,
ability to do daily activities, and overall QoL (scales equivalent to
the CLAS scales used in the present study). Comparison of QoL
scores for the total epoetin alfa population of the three trials with
those for the total placebo population revealed signiﬁcantly
(P50.05) greater improvement in all three QoL parameters in
patients who responded to epoetin alfa (i.e., had a haematocrit
increase 56%) vs patients given placebo. From this, the investiga-
tors concluded that epoetin alfa does improve functional capacity
in anaemic cancer patients when there is an increase in haematocrit.
In the three separate large, open-label, non-placebo-controlled,
community-based surveillance studies with a combined enrolment
of over 7000 patients, large positive changes were noted in Hb
levels and QoL of patients treated with epoetin alfa (Glaspy et al,
1997; Demetri et al, 1998; Gabrilove et al, 2001). Transfusion
requirements also decreased steadily and dramatically throughout
the course of all three studies. These changes were noted even after
accounting for disease progression in two of the studies (Glaspy et
al, 1997; Demetri et al, 1998). The relationship between disease
progression and QoL changes was noted to be similar to the results
we present here, conﬁrming that patients with disease progression
have a much larger deterioration in QoL than those without, but
also concluding that anaemia made a large and independent contri-
bution to QoL in all subgroups of patients. Of note, patients with
disease progression having an improvement in Hb of greater than
2gd L
71 were able to maintain their QoL at or near baseline levels
while those with both disease progression and no improvement in
anaemia experienced deterioration in QoL. Finally, there were
signiﬁcant correlations noted in these studies between Hb change
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love et al, 2001), even after accounting for the effects of disease
progression (Glaspy et al, 1997; Demetri et al, 1998).
Although both the Abels study and the community-based studies
support the main ﬁnding of the present study, each study had
limitations, the most obvious being that the community-based
studies were not placebo-controlled. It is, however, an important
ﬁnding that several large, community-based studies that more
closely represent the actual clinical environment corroborate the
results seen in the present randomised, placebo-controlled study.
The Abels study used visual analogue scales to measure changes
in symptoms and QoL, a method that is recognised in pain assess-
ment and other symptom assessment and has sensitivity in cancer-
symptom assessment. Since then, new instruments such as the
FACT have been developed to augment measurements such as linear
analogue scales; and studies using both measures now report posi-
tive changes in both instruments with anaemia correction (Glaspy
et al, 1997; Demetri et al, 1998). In addition, the Abels study
reported differences in results between patients who received place-
bo and patients who responded to epoetin alfa treatment rather
than reporting results in all patients who received epoetin alfa.
The ﬁnding in the present study of an important role for Hb
levels in increasing and maintaining QoL also is in agreement with
the ﬁndings of two other studies that investigated the impact of
anaemia and fatigue on cancer patients (Cella, 1997; Langer et al,
1997). In one study (Cella, 1997), assessment of QoL based on
the FACT-An showed that patients with Hb levels 412 g dL
71
had signiﬁcantly less fatigue, fewer non-fatigue anaemia symptoms,
better physical and functional well-being, and higher overall QoL
than those with an Hb level 412 g dL
71 (P40.01 for all). The
second study (Langer et al, 1997), using an index based on
FACT-Lung subscales, showed a signiﬁcant correlation (r=0.38,
P40.02), independent of tumour response, between worsening
anaemia and diminishing QoL in patients with non-small-cell lung
cancer by their fourth cycle of chemotherapy. Together with data
presented here, these studies provide objective evidence that
increasing Hb levels in anaemic cancer patients can positively inﬂu-
ence their QoL (Cella, 1997; Glaspy et al, 1997; Langer et al, 1997;
Demetri et al, 1998; Gabrilove et al, 2001).
CONCLUSIONS
In summary, the results of univariate analysis of change scores for
cancer-speciﬁc scales that evaluated QoL in this randomised study
in anaemic patients receiving non-platinum-based chemotherapy
were conﬁrmed by multiple linear regression analysis, which
adjusted for possible differences in demographic and clinical char-
acteristics between the treatment groups as well as tumour
response. Correlation analysis revealed a signiﬁcant positive rela-
tionship between change in Hb level and change in all primary
cancer-speciﬁc QoL endpoints evaluated. These ﬁndings indicate
that epoetin alfa can improve QoL in anaemic cancer patients
undergoing chemotherapy, and this change is associated with
increasing Hb levels. Moreover, the results demonstrate that epoe-
tin alfa treatment and disease progression are independent
contributors to changes in QoL.
In the increasingly cost-contained and cost-conscious clinical
environments in which many European clinicians work, there
might well be reluctance to prescribe a relatively expensive product.
The importance of successfully treating chemotherapy-induced
anaemia by raising Hb levels with epoetin alfa and the concomitant
beneﬁts that this brings for patients’ functioning and well-being are
now clear. Providers are therefore faced with a situation similar to
that experienced with the advent of the 5HT3 antagonists.
Although nausea and vomiting had a severely deleterious effect
on the quality of patients’ lives and these symptoms were always
ranked at the top of lists charting patients’ concerns, some clini-
cians were either reluctant or unable to prescribe the most
efﬁcacious treatments on the grounds of cost. This was eventually
seen as a weak argument, as uncontrolled symptoms that detract
from patients’ QoL can jeopardise completion of treatment and
may have many hidden or unmeasured costs. Consequently,
5HT3 antagonists are now regarded as a standard part of the
management of patients undergoing chemotherapy and this has
transformed the lives of many patients, making chemotherapy
much more tolerable.
Now that nausea and vomiting in chemotherapy have been
signiﬁcantly alleviated, fatigue due to the chemotherapy-induced
anaemia has emerged as a major and distressing problem for
patients (Curt et al, 2000). It is usually poorly understood, often
managed inadequately, and its impact on patients is generally
underestimated. We hope that this study will help to raise aware-
ness that epoetin alfa signiﬁcantly improves Hb levels and reduces
the fatigue that so impairs the QoL of anaemic cancer patients.
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